BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Axim Biotechnologies, Inc. AXIM
13 fiscal years on record · USD · FY2023 reported
SEC FILINGS ONLY
Revenue · FY2023
$39,518
▲ 345.3% vs FY2022
EPS · FY23
$-0.04
Dividend / sh · FY23
—
Payout · FY23
—
ROE · FY23
—
Net margin · FY23
-20395.0%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 39,518.00
Revenue, FY2023 · full 13-year series below
Revenue
Net income
The company lost 20395 cents on every revenue dollar this year.
Per share
USD -0.04
Diluted EPS, FY2023
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2023
ROE
Operating margin-6961.0%
Net margin-20395.0%
Return on assets-193.4%
Returned to shareholders
—
returned in FY2023 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−27.4% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−27.4%
+6.2%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.25B
Shares outstanding, FY2023
Change, 5 years+96.5%
Change, 10 years—
The share count grew 97% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 4.1M
total assets, end of FY2023
Total assetsUSD 4.1M
EquityUSD -7.7M
CashUSD 156,457.00
Gross debtUSD 0.00
Net debtUSD -156,457.00
Current ratio0.03×
The company holds more cash than debt.
History
13 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
·
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
·
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.04
−0.04
0.12
−0.06
−0.10
−0.12
−0.08
−0.17
−0.27
−0.02
0.00
·
0.00
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
·
·
·
·
·
·
·
·
·
−541.2
−27.4
Shares out B
0.25
0.19
0.14
0.13
0.06
0.06
0.05
0.05
0.04
0.03
0.03
0.03
0.03
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
40 of 40
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed